Syndax制药 SNDX 深 沪
等待开盘 03-30 09:30:00 美东时间
23.49
-1.210
-4.90%
华盛通- 最 高24.71
- 今 开24.50
- 成交量 123.46万股
- 最 低 23.445
- 昨 收 24.70
- 总市值 20.72亿
- 52周最高 25.59
- 市盈率 静 --
- 换手率 1.40%
- 52周最低 8.58
- 委 比 65.59%
- 总股本 8820.06万
- 历史最高 29.86
- 量 比 0.78
- 振 幅 5.12%
- 历史最低 3.39
- 每 手 1
- 风险率 4.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
Damora Therapeutics appoints Jennifer Jarrett as President and CEO effective March 30, 2026. Jarrett, with nearly three decades of experience in biotech, tech, and finance, will also join the Board. Biotech leaders Cameron Turtle and Mike Landsittel are added to the Board, while Peter Harwin becomes Chairman. Damora aims to redefine care for blood disorder patients with innovative therapies targeting mutant calreticulin-driven MPNs. The new leade...
03-23 12:00
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
U.S. RESEARCH ROUNDUP-Dow, Oracle, Shopify
U.S. RESEARCH ROUNDUP-Dow, Oracle, Shopify March 9 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Dow, Oracle and Shopify on Monday. HIGHLIGHTS * Dow Inc DOW.N : RBC raises to outperform from sector perform; raises PT t
03-09 15:34
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals granted stock options to three new employees under its 2023 Inducement Plan on March 1, 2026. The options cover up to 81,600 shares, vesting over four years with 25% after one year and the rest vesting monthly over 36 months. The company focuses on advancing innovative cancer therapies, including FDA-approved treatments Revuforj® and Niktimvo™.
03-04 21:01
美股大行评级 | 花旗：维持康菲石油"买入"评级！目标价从125美元升至135美元
今日重点评级关注：HC Wainwright & Co.：维持Helus Pharma"买入"评级，目标价从55美元升至95美元；HC Wainwright & Co.：维持Compass Pathways"买入"评级，目标价从40美元升至70美元
03-03 20:22
Citigroup Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $57
Citigroup analyst Yigal Nochomovitz maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and raises the price target from $51 to $57.
03-03 03:19
财报速睇 | Syndax制药 2025财年Q4营收0.69亿美元，同比增长794.9%；归母净利润亏损0.68亿美元，同比亏损缩窄27.8%
华盛资讯2月27日讯，Syndax制药公布2025财年Q4业绩，公司Q4营收0.69亿美元，同比增长794.9%，归母净利润亏损0.68亿美元，同比亏损缩窄27.8%。
02-27 05:33
Syndax Pharmaceuticals Q4 EPS $(0.78) Misses $(0.58) Estimate, Sales $68.728M Beat $63.968M Estimate.
Syndax Pharmaceuticals (NASDAQ:SNDX) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.58) by 34.48 percent. This is a 29.09 percent increase over losses of $(1.10) per
02-27 05:09
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Syndax Announces Participation in March Investor Conferences
Syndax Pharmaceuticals announced that its CEO, Michael A. Metzger, and management team will participate in three upcoming investor conferences: the TD Cowen 46th Annual Health Care Conference in Boston on March 2, 2026, the Leerink Global Healthcare Conference in Miami Beach on March 11, 2026, and the Barclays 28th Annual Global Healthcare Conference in Miami Beach on March 12, 2026. Fireside chats will be live-streamed and available for replay o...
02-23 12:00
